The results showed that 99% of participants retained antibodies for three months on 88% still had them after six months.

結果顯示，99%的參與者保留了三個月的抗體，88%的參與者在六個月後仍有抗體。

Scientists say the results should provide some reassurance that swift cases of reinfection will be rare.

科學家說，這些結果應該提供一些保證，即迅速的再感染病例將是罕見的。

Naomi Allen, a professor and chief scientist at UK Bio Bank who conducted the study, said that although we cannot be certain how this relates to immunity, the results suggest that people may be protected against subsequent infection for at least six months following natural infection.

進行研究的英國生物銀行教授和首席科學家Naomi Allen表示，雖然我們不能確定這與免疫力有什麼關係，但結果表明，人們在自然感染後至少6個月內可能會受到保護，免受後續感染。

On Wednesday, a pre print study showed that just one shot of the Oxford AstraZeneca vaccine provided sustained protection for three months.

週三，一項印前研究顯示，只需注射一針牛津阿斯利康疫苗就能提供持續三個月的保護。

It showed a 76% efficacy until a second shot was given on higher efficacy.

它顯示出76%的療效，直到在更高的療效上打了第二針。

If the second dose was given at least 12 weeks after the first.

如果第二次劑量是在第一次劑量後至少12周內給予的；

Now that is really good news.

現在，這真是個好消息。

Health Secretary Matt Hancock used this to defend the country's vaccine rollout strategy.

衛生部長馬特-漢考克（Matt Hancock）以此為國家的疫苗推廣戰略辯護。

Britain has extended the gap between doses on given the shot to people of all ages, whereas France Belgium and Germany recommend that Oxfords vaccine is only given toe under 65.

英國已經延長了劑量之間的差距上給所有年齡的人，而法國比利時和德國建議牛欄杆疫苗是隻給 65 歲以下。

Director of the Oxford Vaccine Group, Andrew Pollard said the study was also a success for reducing transmission well that could have, ah really important impact in that it reduces the chances of someone who who is exposed getting the infection, and if they don't get the infection, they can't pass it on, so it decreases the risk, all of transmission in the population.

牛津疫苗組主任安德魯-波拉德說，這項研究也是一個成功的減少傳輸好，可能有，啊真的很重要的影響中，它減少了某人的機會誰是暴露得到的感染，如果他們沒有得到感染，他們不能通過它，所以它減少了風險，所有的人口中的傳輸。

The study's findings are only preliminary ons still under review.

該研究的結果只是初步的，仍在審查中。

It may support Britain's decision to separate doses, but it did not give extra direct evidence of efficacy in older people.

它可能會支持英國決定分開劑量，但它沒有給出額外的直接證據來證明老年人的療效。